Compare Synchrony Financial (SYF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs State Street SPDR S&P Biotech ETF — how do they compare? Synchrony Financial trades at $71.7 (market cap $24.69B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Synchrony Financial pays a 1.63% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Synchrony Financial nearer its low. Which is the better fit depends on your goals.
| SYF | XBI | |
|---|---|---|
Market Cap | $24.69B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $88.47 | $164.28 |
52-Week Low | $63.78 | $85.16 |
Dividend Yield | 1.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
